Ventric Health's CEO, Sean Brady, is leading a team behind a newly FDA-cleared cardiac device designed to address challenges related to heart failure. With heart failure affecting 6.5 million people in the U.S. and leading to significant healthcare costs, the Vivio System offers a noninvasive diagnostic alternative. Using advanced algorithms, the device detects elevated left ventricular end-diastolic pressure (LVEDP), a key metric for heart failure diagnosis. The mobility and simplicity of Vivio make it an attractive option for both clinical and home healthcare settings, providing real-time results in under five minutes. A recent study presented at the American Heart Association Scientific Symposium demonstrated the device's effectiveness, with promising results in terms of sensitivity and specificity.
The technology's focus on noninvasive diagnosis and its adaptability across care settings offer a potential solution to overcome social determinants of health (SDOH) barriers. By enabling clinicians to perform tests for elevated LVEDP in-home or clinic settings, transportation limitations and other barriers to diagnosis can be addressed. The real-time results facilitate immediate discussions between patients and clinicians, positively impacting healthcare literacy and patient understanding. The device's capability to achieve earlier diagnoses aligns with value-based care goals, potentially reducing healthcare costs and improving patient outcomes by enabling lifestyle changes and early management in the earlier stages of heart failure.
Ventric Health aims to change the diagnostic timeline for heart failure, allowing for proactive healthcare management in accessible locations, such as homes and clinics. This shift could lead to cost reduction and improved outcomes through earlier interventions, ultimately supporting physicians and healthcare organisations in delivering more effective care.
Click here to read the original news story.